Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India and China Could Be On The Brink Of A Biosimilars Takeoff, Says One Biotech CEO

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - Asia's giants - India and China - could see a Big Bang-like explosion of biotech- and biosimilar-focused start-ups given the right conditions over the next decade, including an infusion of capital from the West, according to the head of an Indian biopharmaceutical firm

You may also be interested in...



Divi's Gears Up For A Biosimilars Play, Move Comes At The Back Of Demand From Existing Clients

HYDERABAD, India - Years of relationship with large multinational companies has prompted Divi's Labs - one of India's largest contract manufacturers for pharmaceutical raw materials or bulk drugs - to explore a presence in the biosimilars manufacturing space

Divi's Gears Up For A Biosimilars Play, Move Comes At The Back Of Demand From Existing Clients

HYDERABAD, India - Years of relationship with large multinational companies has prompted Divi's Labs - one of India's largest contract manufacturers for pharmaceutical raw materials or bulk drugs - to explore a presence in the biosimilars manufacturing space

Sanofi-Aventis Sees India's Shantha As Global Hub For Its Biotech Plans

MUMBAI - French drug maker Sanofi-Aventis sees Shantha Biotech - its latest Indian acquisition - as a hub to further its global biotech ambitions but may not rush to buy more companies in India

Related Content

UsernamePublicRestriction

Register

SC074387

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel